Novartis inks contract manufacturing deal with Carisma 15-Mar-2022 By Jane Byrne Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.